Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia
Iron overload is a significant concern for patients with thalassemia and often necessitates the use of iron-chelating agents to mitigate the associated complications. Selecting the most appropriate chelation therapy from the available options is a complex decision for healthcare professionals. To su...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmacy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2226-4787/13/3/86 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839653041606754304 |
|---|---|
| author | Saeed Barzegari Hosein Rostamian Ehsan Firoozi-Majd Ibrahim Arpaci |
| author_facet | Saeed Barzegari Hosein Rostamian Ehsan Firoozi-Majd Ibrahim Arpaci |
| author_sort | Saeed Barzegari |
| collection | DOAJ |
| description | Iron overload is a significant concern for patients with thalassemia and often necessitates the use of iron-chelating agents to mitigate the associated complications. Selecting the most appropriate chelation therapy from the available options is a complex decision for healthcare professionals. To support this decision-making process, this study investigates the application of the “Fuzzy Analytic Hierarchy Process” (FAHP) for medication selection in thalassemia patients requiring iron-chelation therapy. In this study, 20 hematologists participated, and matrices related to the FAHP model were used to evaluate three primary iron chelators: deferoxamine, deferasirox, and deferiprone. The results revealed that deferiprone was the most effective choice, while deferasirox outperformed the others in terms of cost and patient satisfaction. Notably, deferoxamine exhibits the highest rate of side effects, followed by deferiprone and deferasirox. The results obtained from the FAHP analysis indicated a consensus among experts and highlighted deferasirox as the optimal choice for treating chronic iron overload in thalassemia patients. The study demonstrates the practical applicability of the FAHP methodology in guiding informed decisions for iron-chelation therapy. It provides insights to help healthcare professionals optimize treatment strategies for patients with thalassemia. |
| format | Article |
| id | doaj-art-7d86ed06b26b49bb94b64b83c295f001 |
| institution | Matheson Library |
| issn | 2226-4787 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmacy |
| spelling | doaj-art-7d86ed06b26b49bb94b64b83c295f0012025-06-25T14:18:42ZengMDPI AGPharmacy2226-47872025-06-011338610.3390/pharmacy13030086Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for ThalassemiaSaeed Barzegari0Hosein Rostamian1Ehsan Firoozi-Majd2Ibrahim Arpaci3Department of Paramedicine, Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Amol 48175-866, IranDepartment of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 14167-53955, IranDepartment of Paramedicine, Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Amol 48175-866, IranManagement Information Systems, College of Business Administration, Gulf University for Science and Technology, Mishref 7207, KuwaitIron overload is a significant concern for patients with thalassemia and often necessitates the use of iron-chelating agents to mitigate the associated complications. Selecting the most appropriate chelation therapy from the available options is a complex decision for healthcare professionals. To support this decision-making process, this study investigates the application of the “Fuzzy Analytic Hierarchy Process” (FAHP) for medication selection in thalassemia patients requiring iron-chelation therapy. In this study, 20 hematologists participated, and matrices related to the FAHP model were used to evaluate three primary iron chelators: deferoxamine, deferasirox, and deferiprone. The results revealed that deferiprone was the most effective choice, while deferasirox outperformed the others in terms of cost and patient satisfaction. Notably, deferoxamine exhibits the highest rate of side effects, followed by deferiprone and deferasirox. The results obtained from the FAHP analysis indicated a consensus among experts and highlighted deferasirox as the optimal choice for treating chronic iron overload in thalassemia patients. The study demonstrates the practical applicability of the FAHP methodology in guiding informed decisions for iron-chelation therapy. It provides insights to help healthcare professionals optimize treatment strategies for patients with thalassemia.https://www.mdpi.com/2226-4787/13/3/86thalassemiafuzzy AHPmedication decision making |
| spellingShingle | Saeed Barzegari Hosein Rostamian Ehsan Firoozi-Majd Ibrahim Arpaci Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia Pharmacy thalassemia fuzzy AHP medication decision making |
| title | Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia |
| title_full | Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia |
| title_fullStr | Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia |
| title_full_unstemmed | Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia |
| title_short | Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia |
| title_sort | application of fuzzy ahp for medication decision making in iron chelating medications for thalassemia |
| topic | thalassemia fuzzy AHP medication decision making |
| url | https://www.mdpi.com/2226-4787/13/3/86 |
| work_keys_str_mv | AT saeedbarzegari applicationoffuzzyahpformedicationdecisionmakinginironchelatingmedicationsforthalassemia AT hoseinrostamian applicationoffuzzyahpformedicationdecisionmakinginironchelatingmedicationsforthalassemia AT ehsanfiroozimajd applicationoffuzzyahpformedicationdecisionmakinginironchelatingmedicationsforthalassemia AT ibrahimarpaci applicationoffuzzyahpformedicationdecisionmakinginironchelatingmedicationsforthalassemia |